Aimmune Therapeutics , which on Friday received U.S. Food and Drug Administration approval for its peanut allergy treatment that’s billed as the first of its kind, is already pursuing an ambitious roll-out strategy.
The company is offering more controlled dosage to help alleviate any allergic reactions over time, and target specific allergens that lead to a reaction. Next stepsAimmune’s treatment mimics a type of therapy already in use by some patients. It introduces tiny amounts of peanut protein over a six-month period, under medical supervision known as oral immunotherapy.
Because there isn’t a cure, it places the burden on parents and children to “strictly avoid exposure to prevent severe and potentially life-threatening reactions,” Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, said in a statement last week.